NCT04951947View on ClinicalTrials.gov

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

June 1, 2025

Conditions

Small-cell Lung Cancer

Interventions

DRUG

JS201 combine with Lenvatinib

JS201 300mg i.v Q2wLenvatinib 8mg po. Qd

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors

lead

Hunan Province Tumor Hospital

OTHER